Published in Haematologica on August 31, 2011
Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies. Eur J Hum Genet (2016) 0.75
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Syndromic mental retardation with thrombocytopenia due to 21q22.11q22.12 deletion: Report of three patients. Am J Med Genet A (2010) 1.70
Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. Leuk Res (2009) 1.67
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood (2008) 1.65
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood (2009) 1.65
Familial myelodysplastic syndromes: a review of the literature. Haematologica (2011) 1.36
Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood (2008) 1.19
A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia (2009) 0.97
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol (2010) 3.88
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science (2005) 3.58
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol (2011) 3.17
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol (2011) 3.09
The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol (2006) 3.03
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood (2006) 2.87
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood (2012) 2.69
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol (2010) 2.38
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol (2010) 2.31
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol (2011) 2.26
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol (2009) 2.23
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med (2010) 2.11
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell (2007) 1.96
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood (2010) 1.96
Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood (2006) 1.93
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res (2005) 1.84
Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet (2008) 1.82
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood (2005) 1.82
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol (2011) 1.79
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood (2012) 1.68
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood (2003) 1.65
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood (2011) 1.65
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol (2010) 1.64
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest (2007) 1.63
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood (2013) 1.62
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol (2010) 1.57
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood (2010) 1.56
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res (2012) 1.44
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood (2004) 1.39
Two different del(5q) clones in a patient with myelodysplastic syndrome. Leuk Lymphoma (2011) 1.39
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood (2002) 1.38
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood (2007) 1.37
Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology (2012) 1.37
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol (2012) 1.36
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer (2005) 1.34
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood (2013) 1.33
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica (2010) 1.32
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica (2009) 1.31
The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood (2007) 1.31
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood (2011) 1.30
Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene (2003) 1.27
CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology (2005) 1.25
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood (2012) 1.25
Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol (2006) 1.25
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet (2011) 1.23
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood (2009) 1.23
Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum (2005) 1.23
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica (2005) 1.21
Refined histopathologic scoring system improves power to detect colitis QTL in mice. Mamm Genome (2004) 1.20
Radiation rescue: mesenchymal stromal cells protect from lethal irradiation. PLoS One (2011) 1.17
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol (2009) 1.17
MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer (2011) 1.15
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet (2005) 1.15
Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res (2005) 1.14
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer (2010) 1.13
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood (2013) 1.12
Replication timing influences DNA copy number determination by array-CGH. Biotechniques (2013) 1.12
Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest (2013) 1.11
Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood (2004) 1.11
Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 1.09
Cd14, Gbp1, and Pla2g2a: three major candidate genes for experimental IBD identified by combining QTL and microarray analyses. Physiol Genomics (2006) 1.08
The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J Clin Invest (2010) 1.07
Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica (2011) 1.06
Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. Eur J Hum Genet (2007) 1.05
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med (2012) 1.05
Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood (2010) 1.05
Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas. Genes Chromosomes Cancer (2006) 1.04
Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood (2012) 1.04
Mesengenic progenitor cells derived from human placenta. Tissue Eng (2004) 1.03
Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol (2011) 1.02